Omeprazole Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 63 pharmaceutical companies such as HORIZON, STRIDES PHARMA, CUMBERLAND and others. It is marketed under 15 brand names, including VIMOVO, OMEPRAZOLE AND SODIUM BICARBONATE, OMECLAMOX-PAK and others. Available in 25 different strengths, such as EQ 20MG BASE;375MG, EQ 20MG BASE;500MG, 40MG;1.1GM and others, and administered through 9 routes including TABLET, DELAYED RELEASE;ORAL, CAPSULE;ORAL, CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL and others.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 63 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"84250","ingredient":"OMEPRAZOLE","trade_name":"OMEPRAZOLE","family_id":"83a755b3ce114230bf5f","publication_number":"US9023391B2","cleaned_patent_number":"9023391","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-08-16","publication_date":"2015-05-05","legal_status":"Granted"} US9023391B2 Formulation 05 May, 2015 Granted 16 Aug, 2025
{"application_id":"84412","ingredient":"ASPIRIN; OMEPRAZOLE","trade_name":"YOSPRALA","family_id":"438a1a6e6b2f48b9b02d","publication_number":"US9987231B2","cleaned_patent_number":"9987231","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-01-02","publication_date":"2018-06-05","legal_status":"Expired"} US9987231B2 05 Jun, 2018 Expired 02 Jan, 2033
{"application_id":"84404","ingredient":"ASPIRIN; OMEPRAZOLE","trade_name":"YOSPRALA","family_id":"438a1a6e6b2f48b9b02d","publication_number":"US9539214B2","cleaned_patent_number":"9539214","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-03-13","publication_date":"2017-01-10","legal_status":"Granted"} US9539214B2 10 Jan, 2017 Granted 13 Mar, 2033
{"application_id":"43993","ingredient":"AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN","trade_name":"TALICIA","family_id":"771a08de1e60447691ed","publication_number":"US9603806B2","cleaned_patent_number":"9603806","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-02-12","publication_date":"2017-03-28","legal_status":"Granted"} US9603806B2 Formulation 28 Mar, 2017 Granted 12 Feb, 2034
{"application_id":"44022","ingredient":"AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN","trade_name":"TALICIA","family_id":"771a08de1e60447691ed","publication_number":"US11135172B2","cleaned_patent_number":"11135172","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-02-12","publication_date":"2021-10-05","legal_status":"Granted"} US11135172B2 Formulation 05 Oct, 2021 Granted 12 Feb, 2034
{"application_id":"44019","ingredient":"AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN","trade_name":"TALICIA","family_id":"771a08de1e60447691ed","publication_number":"US9498445B2","cleaned_patent_number":"9498445","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-02-12","publication_date":"2016-11-22","legal_status":"Granted"} US9498445B2 Formulation 22 Nov, 2016 Granted 12 Feb, 2034
{"application_id":"44018","ingredient":"AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN","trade_name":"TALICIA","family_id":"771a08de1e60447691ed","publication_number":"US9050263B2","cleaned_patent_number":"9050263","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-02-12","publication_date":"2015-06-09","legal_status":"Patented case"} US9050263B2 Formulation 09 Jun, 2015 Patented case 12 Feb, 2034
{"application_id":"44023","ingredient":"AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN","trade_name":"TALICIA","family_id":"771a08de1e60447691ed","publication_number":"US11931463B2","cleaned_patent_number":"11931463","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-02-12","publication_date":"2024-03-19","legal_status":"Granted"} US11931463B2 Formulation 19 Mar, 2024 Granted 12 Feb, 2034
{"application_id":"44020","ingredient":"AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN","trade_name":"TALICIA","family_id":"771a08de1e60447691ed","publication_number":"US10238606B2","cleaned_patent_number":"10238606","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-02-12","publication_date":"2019-03-26","legal_status":"Granted"} US10238606B2 Formulation 26 Mar, 2019 Granted 12 Feb, 2034
{"application_id":"88651","ingredient":"ESOMEPRAZOLE MAGNESIUM","trade_name":"ESOMEPRAZOLE MAGNESIUM","family_id":"92af39aa7e1f4c149351","publication_number":"US10076494B2","cleaned_patent_number":"10076494","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-12-08","publication_date":"2018-09-18","legal_status":"Granted"} US10076494B2 Formulation 18 Sep, 2018 Granted 08 Dec, 2036
{"application_id":"88655","ingredient":"ESOMEPRAZOLE MAGNESIUM","trade_name":"ESOMEPRAZOLE MAGNESIUM","family_id":"92af39aa7e1f4c149351","publication_number":"US10835488B2","cleaned_patent_number":"10835488","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-12-08","publication_date":"2020-11-17","legal_status":"Granted"} US10835488B2 Formulation 17 Nov, 2020 Granted 08 Dec, 2036
{"application_id":"115155","ingredient":"OMEPRAZOLE; SODIUM BICARBONATE","trade_name":"KONVOMEP","family_id":"55007e17fde74106b3b1","publication_number":"US12042539B2","cleaned_patent_number":"12042539","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-07-16","publication_date":"2024-07-23","legal_status":"Granted"} US12042539B2 Formulation 23 Jul, 2024 Granted 16 Jul, 2039
{"application_id":"108481","ingredient":"OMEPRAZOLE; SODIUM BICARBONATE","trade_name":"KONVOMEP","family_id":"0bf8116074f74cdb8fac","publication_number":"US20220031683A1","cleaned_patent_number":"12329752","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-07-16","publication_date":"2022-02-03","legal_status":"Pending"} US12329752B2 Formulation 03 Feb, 2022 Pending 16 Jul, 2039
{"application_id":"115154","ingredient":"OMEPRAZOLE; SODIUM BICARBONATE","trade_name":"KONVOMEP","family_id":"55007e17fde74106b3b1","publication_number":"US11911473B2","cleaned_patent_number":"11911473","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-07-16","publication_date":"2024-02-27","legal_status":"Granted"} US11911473B2 27 Feb, 2024 Granted 16 Jul, 2039
{"application_id":"108479","ingredient":"OMEPRAZOLE; SODIUM BICARBONATE","trade_name":"KONVOMEP","family_id":"0bf8116074f74cdb8fac","publication_number":"US11103492B2","cleaned_patent_number":"11103492","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-07-16","publication_date":"2021-08-31","legal_status":"Granted"} US11103492B2 Formulation 31 Aug, 2021 Granted 16 Jul, 2039
{"application_id":"108475","ingredient":"OMEPRAZOLE; SODIUM BICARBONATE","trade_name":"KONVOMEP","family_id":"0bf8116074f74cdb8fac","publication_number":"US10751333B1","cleaned_patent_number":"10751333","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-07-16","publication_date":"2020-08-25","legal_status":"Granted"} US10751333B2 Formulation 25 Aug, 2020 Granted 16 Jul, 2039
{"application_id":"108482","ingredient":"OMEPRAZOLE; SODIUM BICARBONATE","trade_name":"KONVOMEP","family_id":"55007e17fde74106b3b1","publication_number":"US11633478B2","cleaned_patent_number":"11633478","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-07-16","publication_date":"2023-04-25","legal_status":"Granted"} US11633478B2 Formulation 25 Apr, 2023 Granted 16 Jul, 2039
{"application_id":"108480","ingredient":"OMEPRAZOLE; SODIUM BICARBONATE","trade_name":"KONVOMEP","family_id":"55007e17fde74106b3b1","publication_number":"US11771686B2","cleaned_patent_number":"11771686","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-03-01","publication_date":"2023-10-03","legal_status":"Granted"} US11771686B2 03 Oct, 2023 Granted 01 Mar, 2040
{"application_id":"122881","ingredient":"AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN","trade_name":"TALICIA","family_id":"","publication_number":"US11878011B2","cleaned_patent_number":"11878011","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2042-05-27","publication_date":"2024-01-23","legal_status":"Granted"} US11878011B2 23 Jan, 2024 Granted 27 May, 2042

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Omeprazole

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.